The Valley Desk

NCT06695845 · Interventional trial

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

Overall registry status Recruiting

Phase 2

Conditions Breast Cancer, Colorectal Cancer, Endometrial Cancer, Esophageal Cancer, Gastric Cancer, Gastroesophageal Cancer, HER-2 Protein Overexpression, Non-small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Salivary Gland Cancer, Urothelial Carcinoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov